Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Alirocumab and cardiovascular outcomes after acute coronary syndrome
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Alirocumab and cardiovascular outcomes after acute coronary syndrome'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cardiovascular Outcomes
100%
Acute Coronary Syndrome
100%
Alirocumab
100%
Placebo Groups
33%
Low-density Lipoprotein Cholesterol Level
33%
Confidence Interval
22%
Hazard Ratio
22%
Placebo
22%
Statin Therapy
22%
Cardiovascular Events
22%
Monoclonal Antibody
11%
High Risk
11%
Coronary Artery Disease
11%
Ischemic Stroke
11%
Adverse Events
11%
High-density Lipoprotein Cholesterol (HDL-C)
11%
High-intensity Statin Therapy
11%
Hospitalization
11%
Cholesterol Levels
11%
Stable Angina
11%
Nonfatal Myocardial Infarction
11%
Non-fatal
11%
Randomized Placebo-controlled Trial
11%
Apolipoprotein B (Apo B)
11%
Local Injection Site Reaction
11%
Maximum Tolerated Dose
11%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
11%
Absolute Benefit
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
100%
Alirocumab
100%
Placebo
66%
Statin (Protein)
33%
Low Density Lipoprotein Cholesterol
33%
Adverse Event
11%
Heart Infarction
11%
Brain Ischemia
11%
Ischemic Heart Disease
11%
Unstable Angina Pectoris
11%
Lipoprotein
11%
Injection Site Reaction
11%
Apolipoprotein B
11%
Maximum Tolerated Dose
11%
Human Monoclonal Antibody
11%
Proprotein Convertase 9
11%